TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Novavax, Inc. (NASDAQ:NVAX ... we expect to complete database lock of a related pediatric clinical trial in the fourth ...

Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing ... today announced that Water Tower Research... Catheter Precision, Inc. , a U.S.-based innovative medical ...